WASHINGTON, D.C. (December 22, 2009) — The National Osteoporosis Foundation (NOF) has named Amy McGuire Porter the new Executive Director and CEO of the Foundation effective February 1, 2010. Ms. Porter joins NOF with more than twenty years experience in the nonprofit sector. Porter's most recent position was as Executive Director of the Foundation for the National Institutes of Health. She has played key roles in executive, communications and development positions, working to further the missions of many forward thinking and visible institutions in the D.C. area.
"The Board of Trustees is fortunate to welcome Ms. Porter as our new Executive Director. She possesses a diverse skill set that will be critical to the advancement of the National Osteoporosis Foundation," said NOF Chairman the Honorable Daniel A. Mica.
"We are very pleased to have Ms. Porter assume the leadership role at NOF," said Robert R. Recker, M.D., President of the NOF Board of Trustees. "Amy brings a dedication and professional expertise that we are confident will serve the Foundation, patients, healthcare professionals and community well."
As she begins her position at NOF, Porter will work closely with the NOF Board of Trustees, staff and partners to continue to position the Foundation as the premier osteoporosis nonprofit organization so that it can advance bone health and osteoporosis to the top of the national healthcare agenda and lower the incidence of osteoporosis in the United States.
"I am pleased to join the team at NOF as Executive Director and CEO. This position offers me the opportunity to combine my passion for health-related nonprofit work with my respect for the mission of this Foundation. I look forward to bringing my experience to the work that is being done here."
Established in 1984, the National Osteoporosis Foundation, a leading community-focused health organization, is dedicated to the prevention of osteoporosis and broken bones, the promotion of strong bones for life and the reduction of human suffering through programs of awareness, education, advocacy and research. For more information on the National Osteoporosis Foundation, visit www.nof.org.
Last week, a Food and Drug Administration (FDA) Panel voted that the risks of calcitonin salmon outweigh the benefits for the treatment of postmenopausal osteoporosis. The panel joined health authorities around the world in reviewing the drug’s safety after two recent studies showed slightly higher rates of cancer among patients taking calcitonin. The panel voted against continued use of the drug by a narrow majority, pointing out that it has not been found very effective in preventing bone fractures.
In today's Washington Post article "Calcium and Vitamin D findings show that caring for your bones can be compilicated," NOF's senior clinical director, Dr. Felicia Cosman helps clear up some of the confusion around the recent and conflicting research on calcium and vitamin D. She says: "It’s confusing, even for doctors. But there’s a common thread: None of the heart or kidney risks were associated with calcium from food."
CIRCA, the leading international buyer of fine jewelry, diamonds and watches, announced a new partnership with NOF at a Generations of Strength luncheon at the Friars Club in New York City on February 26. To kick-off the partnership, CIRCA’s Acting CEO Mary L. Forté presented NOF Executive Director and CEO Amy Porter with a check for $25,000, to support NOF’s mission.